Metforminijev Klorid Lek

Metformin Hydrochloride, the active ingredient in Metforminijev Klorid Lek, is a biguanide presented as an oral dosage form for oral use. It is used to improve blood glucose control in adults with type 2 diabetes mellitus. GNH USA supplies Metforminijev Klorid Lek as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin Hydrochloride acts on glucose metabolism and is indicated for conditions within the antidiabetic therapeutic area. - Type 2 diabetes mellitus: lowers elevated blood glucose by reducing hepatic glucose output and enhancing peripheral insulin sensitivity. - Prediabetes (impaired glucose tolerance): helps delay progression to overt diabetes through modest glucose reduction. - Polycystic ovary syndrome (off‑label): may improve insulin resistance and restore ovulatory function.

Metformin Hydrochloride is associated with several adverse reactions that vary in frequency.

Common Side Effects: - Nausea: mild to moderate gastrointestinal discomfort. - Diarrhea: loose stools, often transient. - Abdominal pain: cramping or discomfort. - Metallic taste: transient alteration of taste perception. - Weight loss: modest reduction in body weight. - Vitamin B12 deficiency: decreased absorption over long‑term use.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic acidosis. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatic failure: marked liver enzyme elevation. - Hypoglycemia: uncommon when used alone, more likely with concomitant insulin or sulfonylureas. - Acute pancreatitis: very rare inflammatory condition of the pancreas. - Anemia: due to reduced red blood cell production.

Metformin Hydrochloride requires careful patient assessment before and during therapy. - Renal function: assess creatinine clearance; avoid if severe renal impairment. - Hepatic function: monitor liver enzymes; use with caution in hepatic disease. - Cardiovascular status: avoid in acute or chronic heart failure due to lactic acidosis risk. - Elderly patients: start at lower dose and monitor for accumulation. - Concomitant alcohol: limit intake to reduce lactic acidosis risk. - Store at room temperature: keep in the original container, protect from moisture and heat.

Metformin Hydrochloride can interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure and increase lactic acidosis risk. - Cimetidine: can raise metformin plasma concentrations. - Alcohol: potentiates risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycemia symptoms. - Diuretics: can affect renal clearance of metformin. - ACE inhibitors/ARBs: monitor renal function and potassium. - NSAIDs: may reduce renal perfusion, increasing metformin levels. - Calcium channel blockers: occasional reports of altered glucose control.